Ipsen’s failure comes shortly after Regeneron’s FOP study met its endpoints, sparking an FDA approval submission.
The results indicate that pemvidutide achieved significant reductions in primary non-invasive markers of fibrosis.
With several sites activated and recruitment ongoing, the Phase IIb trial is projected to deliver top-line outcomes next year.
Lilly has now submitted a new drug application (NDA) for orforglipron to the FDA for use in adults with obesity.
Takeda’s oral PsO candidate met its primary and secondary endpoints in two Phase III trials.
The study protocol comprises dose-expansion and dose-escalation phases and aims to assess the efficacy and safety of QT-019B.
